4.7 Review

The Promise and Perils of Stem Cell Therapeutics

Journal

CELL STEM CELL
Volume 10, Issue 6, Pages 740-749

Publisher

CELL PRESS
DOI: 10.1016/j.stem.2012.05.010

Keywords

-

Funding

  1. NIH [R24DK092760, UO1-HL100001, RC4-DK090913, P50HG005550]
  2. ARRA [RC2-HL102815]
  3. Roche Foundation for Anemia Research
  4. Alex's Lemonade Stand
  5. Ellison Medical Foundation
  6. Doris Duke Medical Foundation
  7. Harvard Stem Cell Institute

Ask authors/readers for more resources

Stem cells are the seeds of tissue repair and regeneration and a promising source for novel therapies. However, apart from hematopoietic stem cell (HSC) transplantation, essentially all other stem cell treatments remain experimental. High hopes have inspired numerous clinical trials, but it has been difficult to obtain unequivocal evidence for robust clinical benefit. In recent years, unproven therapies have been widely practiced outside the standard clinical trial network, threatening the cause of legitimate clinical investigation. Numerous challenges and technical barriers must be overcome before novel stem cell therapies can achieve meaningful clinical impact.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available